Short answer
Celcuity Inc. (CELC) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Celcuity announced financial results for the quarter ended September 30, 2026.
Celcuity Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Celcuity announced financial results for the quarter ended September 30, 2026
- Full revenue, earnings and cash-flow details are in Exhibit 99.1, the accompanying results release
Item EX-99.1 · Exhibit EX-99.1
- REVTORPYK launch gaining access: 91% of U.S. commercial and Medicare lives covered, while 78% of 36 strategic accounts have ordered
- Early reach broad but revenue absent: shipments began September 30, yet no product revenue recognized in Q3
- Launch investment sharply increased SG&A to $39.8M from $12.4M, driving net loss to $73.3M versus $43.8M
- Cash, cash equivalents and short-term investments totaled $642.7M after a $50.0M Pfizer approval payment, funding operations through 2029
- Mutant-cohort sNDA expands potential market, while VIKTORIA-2 and prostate cancer trials preserve longer-term growth catalysts
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Celcuity Inc. 8-K filings
Get the next CELC 8-K as it lands
Follow CELC for push alerts, or ask the research agent what this filing means.